Anika Therapeutics Inc. (ANIK) and Morphic Holding Inc. (NASDAQ:MORF) Contrasting side by side

Anika Therapeutics Inc. (NASDAQ:ANIK) and Morphic Holding Inc. (NASDAQ:MORF), both competing one another are Biotechnology companies. We will compare their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anika Therapeutics Inc. 54 2.44 13.96M 2.16 26.56
Morphic Holding Inc. 17 0.00 8.80M -0.97 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents Anika Therapeutics Inc. (NASDAQ:ANIK) and Morphic Holding Inc. (NASDAQ:MORF)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Anika Therapeutics Inc. 25,967,261.90% 11.6% 10.4%
Morphic Holding Inc. 53,044,002.41% 0% 0%

Liquidity

Anika Therapeutics Inc.’s Current Ratio is 20 while its Quick Ratio is 17.7. On the competitive side is, Morphic Holding Inc. which has a 9.7 Current Ratio and a 9.7 Quick Ratio. Anika Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Morphic Holding Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for Anika Therapeutics Inc. and Morphic Holding Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Anika Therapeutics Inc. 1 1 1 2.33
Morphic Holding Inc. 0 0 1 3.00

The downside potential is -3.03% for Anika Therapeutics Inc. with average target price of $46.33. On the other hand, Morphic Holding Inc.’s potential upside is 50.00% and its average target price is $30. The results provided earlier shows that Morphic Holding Inc. appears more favorable than Anika Therapeutics Inc., based on analyst opinion.

Institutional & Insider Ownership

Institutional investors owned 99.3% of Anika Therapeutics Inc. shares and 53.9% of Morphic Holding Inc. shares. 0.8% are Anika Therapeutics Inc.’s share owned by insiders. On the other hand, insiders owned about 24.8% of Morphic Holding Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Anika Therapeutics Inc. -0.55% -4.96% 4.32% 43.88% 78.84% 71.02%
Morphic Holding Inc. 3.34% 16.22% -21.63% 0% 0% -8.83%

For the past year Anika Therapeutics Inc. has 71.02% stronger performance while Morphic Holding Inc. has -8.83% weaker performance.

Summary

Anika Therapeutics Inc. beats on 9 of the 13 factors Morphic Holding Inc.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The companyÂ’s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.